PK-group | 11. February 2011
Peer review publications for the PK-group since 2000.
2000
1.Åsberg A, Berg KJ, Hartmann A. Each administration of cyclosporine A enhances skin microvascular reactivity in renal transplant recipients. Microvasc Res 2000; 60 (2): 81-90.
2.Molden E, Åsberg A, Christensen H. CYP2D6 is involved in O-demethylation of diltiazem – An in vitro study with transfected human liver cells. Eur J Clin Pharmacol 2000; 56: 575-579.
3.Breivik, E.K., Bjørnsson, G., and Skovlund, E. A comparison of pain rating scales by sampling from clinical trial data. Clin. J. Pain 2000; 16: 22-28.
4.Hernandez, A.M., Fosså, S.D., Brøgger, A., Kat, A., and Skovlund, E. Chromosome aberrations after etoposide containing cisplatin-based chemotherapy for malignant germ-cell tumours. Ann. Onco 2000; 11: 897-898.
5.Alfsen, G.C., Thoresen, S.Ø., Kristensen, G.B., Skovlund, E., and Abeler, V.M. Histopathological subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups. A population based study with review of all non-squamous cervical carcinomas in Norway from 1966-70, 1976-80, and 1986-90. Cancer 2000; 89: 1291-1299.
6.Skovlund, E. and Fosså, S.D. PSA-screening i tre norske fylker i 1999. Tidsskr. Nor. Lægeforen 2000; 120: 2539-2541.
7.Skarstein, J., Aass, N., Fosså, S.D., Skovlund, E., and Dahl, A.A. Psychological distress in cancer patients as measured by the Hospital Anxiety and Depression Scale (HADS) and the EORTC QLQ-C33. J Psychosomatic Res 2000; 49: 27-34.
8.Lilleby,W., Fosså, S.D., Knutsen, B.H., Abildgaard, A., Skovlund, E., and Lien, H.H. Computed tomography / magnetic resonance based volume changes of the primary tumour in prostate assessed in patients with prostate cancer with or without androgen deprivation. Radiother. Oncol 2000; 57: 195-200.
9.Laake, K., Vu, P., Andersen, T.I., Erikstein, B., Kåresen, R., Lønning, P.E., Skovlund, E., and Børresen-Dale, A-L. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. Br. J. Cancer 2000; 83: 1650-1653.
10.Molden E, Christensen H and Sund RB. Extensive metabolism of diltiazem and P-glycoprotein mediated efflux of desacetyl-diltiazem by the rat jejunum in vitro. Drug Metabolism and Disposition 2000; 28: 107-109.
2001
11.Åsberg A, Midtvedt K, Vassbotn T, Hartmann A. Better microvascular function on long-term treatment with lisinopril than nifedipine. Nephrol Dial Transplant, 2001; 16: 1465-1470.
12.Åsberg A, Holdaas H, Fjeldså E, Hartmann A. Atorvastatin improves endothelial function in renal transplant recipients. Nephrol Dial Transplant, 2001; 16: 1920-1924.
13.Åsberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant, 2001; 1(4): 382-386.
14.Molden E, Åsberg A. Metabolic interactions with statins. [Norwegian]. Tidsskr Nor Lægeforen 2001; 121: 189-193.
15.Witczak BJ, Åsberg A, Hartmann A. Acute dialysis-dependent renal failure at the Rikshospital in 1998 [Norwegian]. Tidsskr Nor Lægeforen, 2001; 121: 1216-1219.
16.Skovlund, E. and Fenstad, G.U. Should we always choose a non-parametric test when comparing two apparently non-normal distributions? J. Clin. Epidemiol 2001; 54: 86-92.
17.Lilleby, W., Paus, E., Skovlund, E., and Fosså, S.D. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. The Prostate 2001; 46: 126-133.
18.Fodstad, Ø., Faye, R., Høifødt, H.K., Skovlund, E., Aamdal, S. Immunobead-based detection and characterization of circulating tumor cells in melanoma patients. Rec. Res. in Cancer Res 2001; 158: 40-50.
19.Skovlund, E. Hva kjennetegner en god legemiddelutprøvning? Tidsskr. Nor. Lægeforen 2001; 121: 336-338.
20.Breivik, E.K. and Skovlund, E. (Comparing pain rating scales in clinical trials (letter). Clin. J. Pain 2001; 17: 104-105.
21.Lilleby, W. Torlakovic, G., Torlakovic, E., Skovlund, E., and Fosså, S.D. Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy. Cancer 2001; 92: 311-319.
22.Holm, R., Skovlund, E., Skomedal, H., Flørenes, V.A., and Tanum, G. Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas. Histopathology 2001; 39: 43-49.
23.Røtterud, R., Berner, Å., Holm, R., Skovlund, E., and Fosså, S.D. p53, p21 and mdm2 expression versus response to radiotherapy in transitional carcinoma of the bladder. BJU International 2001; 88: 202-208.
24.Hall, K.S., Wiklund, T., Erikstein, B., Holte. H., Kvalheim, G., Sommer, H.H., Andersen, A., Skovlund, E., Bergh, J., and Hall, C. Effects of dose-intensive chemotherapy and radiotherapy on serum N-terminal proatrial natriuretic peptide in high-risk breast cancer patients. Breast Cancer Res & Treat 2001; 67: 235-244.
25.Suo, Z., Yang, H., Mei, Q., Skovlund, E., Cui, J., and Nesland, J.M. Type 1 protein tyrosine kinases in Chinese breast carcinomas: A clinicopathological study. Int. J. Surg. Pathol 2001; 9: 177-187.
26.Røtterud, R., Skomedal, H., Berner, Å., Danielsen, H.E., Skovlund, E., and Fosså, S.D. p53 and p21 WAF1/CIP1 behave differently in euploid vs aneuploid bladder tumours treated with radiotherapy. Acta Oncologica 2001; 40: 644-652.
27.Alfsen, G.C., Kristensen, G.B., Skovlund, E., Pettersen, E., and Abeler, V.M. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: A population based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer 2001; 92: 2471-2483.
28.Fosså, S.D., Eri, L.M., Skovlund, E., Tveter, K., Vatten, L. No randomized trial of prostate cancer screening in Norway. Lancet Oncol 2001; 2: 741-745.
2002
29.Molden E, Åsberg A, Christensen H. Desacetyl-diltiazem (M1) displays several fold higher affinity to CYP2D6 compared to CYP3A4. Drug Metabolism and Disposition, 2002; 30(1): 1-3.
30.Øie E, Yndestad A, Robins S, Bjørnerheim R, Åsberg A, Attramadal H. Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. Basic Res Cardiol 2002; 97: 239-247.
31.Hermann M, Åsberg A, Rebusaet JLE, Sæther S, Berg KJ, Christensen H. Intake of grapefruit juice alters the metabolic pattern of cyclosporine A in renal transplant recipients. Int J Clin Pharmacol Ther 2002; 40(10): 451-456.
32.Christensen H, Åsberg A, Holmboe ÅB, Berg KJ. Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol 2002; 58: 515-520.
33.Molden E, Johansen PW, Bøe GH, Bergan S, Christensen H, Rugstad HE, Rootwelt H, Reubsaet L, Lehne G. Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype. ClinPharmacol Ther 2002;72:333-42.
34.Suo, Z., Risberg, B., Kalsson, M.G., Willman, K., Tierens, A., Skovlund, E., and Nesland, J.M. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J. Pathol 2002; 196: 17-25.
35.Sandven, P., Qvist, H., Skovlund, E., and Giercksky, K.E. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30: 541-547.
36.Bretthauer, M., Thiis-Evensen, E., Huppertz-Hauss, G., Gisselsson, L., Grotmol, T., Skovlund, E., and Hoff, G. NORCCAP (NORwegian Colorectal CAncer Prevention): a randomised trial to assess the safety and efficacy of carbon dioxide versus air insufflation in colonoscopy. Gut 2002; 50: 604-607.
37.Puska, P., Korpelainen, V., Høie, L., Skovlund, E., Lahti, T., and Smerud, K.T. Soy protein in hypercholesterolemia: A double blind, placebo controlled trial. Eur. J. Clin. Nutr 2002; 56: 352-357.
38.Bretthauer, M., Gondal, G., Larsen, I.K., Carlsen, E., Eide, T.J., Grotmol, T., Skovlund, E., Tveit, K.M., Vatn, M.H., and Hoff, G. Design, organisation and management of a controlled population screening study for detection of colorectal neoplasia. Attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention). Scand J Gastroenterol 2002; 37: 568-573.
39.Fosså, S.D. and Skovlund, E. Selection of patients may limit the generalizability of results from cancer trials. Acta Oncol 2002; 41: 131-137.
40.Heimdal, K., Skovlund, E., Møller, P. Oral contraceptives and risk of familial breast cancer. Cancer Detection and Prevention 2002; 26: 23-27.
41.Lund, K., Refsnes, M., Ramis, I., Dunster, C. Boe, J., Schwarze, P.E., Skovlund, E., Kelly, F.J., and Kongerud, J. Human exposure to hydrogen fluoride induces acute neutrophilic, eicosanoid, and antioxidant changes in nasal lavage fluid. Inhalation Toxicology 2002; 14: 119-132.
42.Suo, Z., Risberg, B., Kalsson, M.G., Willman, K., Skovlund, E., and Nesland, J.M. The expression of EGFR family ligands in breast carcinomas. Int. J. Surg. Pathol 2002; 10: 91-99.
43.Hollender, Å., Kvaløy, S., Nome, O., Skovlund, E., Lote, K., and Holte, H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma. A risk model. Ann. Oncol 2002; 13: 1099-1107.
44.Søreide, J.A., Varhaug, J.E., Fjøsne, H.E., Erikstein, B, Jacobsen, A.-B., Skovlund, E., and Kvinnsland, S. Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur J Surg Oncol 2002; 28: 505-510.
45.Bretthauer, M., Hoff, G., Thiis-Evensen, E., Grotmol, T., Thorp Holmsen, S., Moritz, V., and Skovlund, E Carbon dioxide insufflation reduces discomfort due to flexible sigmoidoscopy in colorectal cancer screening. Scand J Gastroenterol 2002; 37: 1103-1107.
46.Lindbæk, M. and Skovlund, E. Kontrollerte kliniske forsøk – jakten på sann effekt av behandling. Tidsskr Nor Lægeforen 2002; 122: 2631-2635.
47.Bretthauer, M., Hoff, G., Thiis-Evensen, E., Grotmol, T., Larsen, I.K., Kjellevold, Ø., and Skovlund, E. Use of a disposable sheath system for flexible sigmoidoscopy in decentralized colorectal cancer screening. A randomised controlled trial. Endoscopy 2002; 34: 814-818.
48.Sundstrøm, S., Bremnes, R.M., Kaasa, S., Aasebø, U., Hatlevoll, R., Dahle, R., Boye, N., Wang, M., Vigander, T., Vilsvik, J., Skovlund, E., Hannisdal, E., and Aamdal, S. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 2002; 20: 4665-4672.
49.Hermann M, Christensen H and Reubsaet JLE. Evaluation of essential parameters in the chromatographic determination of cyclosporine A and metabolites using a D-optimal design. J. Pharm. Biomed. Anal. 2002; 30: 1263-1276.
2003
50.Åsberg A. Interactions between cyclosporine A and lipid-lowering drugs: Implications for organ transplant recipients. Drugs 2003; 63(4): 367-378.
51.Åsberg A, Holdaas H, Jardine AG, Edvardsen C, Hartmann A. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin Transpl 2003; 17(4): 385-390.
52.Sagedal S, Nordal KP, Hartmann A, Midtvedt K, Foss A, Åsberg A, Degré M, Fauchald P, Rollag H. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomised, comparative study. Nephrol Dial Transplant 2003; 18(9): 1899-1908.
53.Molden E, Bøe GH, Christensen H, Reubsaet L. Development of a high-performance liquid chromatography-mass spectrometry method for analyzing diltiazem and 11 of its phase I metabolite in human plasma. J Pharm Biomed Anal 2003;33:275-85.
54.Wangensteen H, Molden E, Christensen H, Malterud KE. Isolation and characterisation of CYP3A4 inhibitors in grapefruit peel. Eur J Clin Pharmacol 2003;58:663-68.
55.Torlakovic, E., Skovlund, E., Snover, D. L., Torlakovic, G., and Nesland, J.M. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol 2003; 27: 65-81.
56.Moe, T.J., Mykletun, A.., Matre, R., Skovlund, E., Bassøe, C.F., and Dahl, A.A. Change of immunoglobulins and complement factors in patients with self-injurious behaviour. Acta Psychiatr Scand 2003; 107: 151-154.
57.Diep, C.B., Thorstensen, L., Meling, G.I., Skovlund, E., Rognum, T.O., and Lothe, R.A. Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J Clin Oncol 2003; 21: 820-829.
58.Guren, M.G., Dueland, S., Skovlund, E., Fosså, S.D., Poulsen, J.P., and Tveit, K.M. Quality of life during radiation therapy for rectal cancer. Eur J Cancer 2003; 39: 587-594.
59.Rønning, M., Blix, H.S., Strøm, H., Skovlund, E., Andersen, M., and VanderStichele, R. Problems in collecting comparable national drug use data in Europe: the example of antibacterials. Eur J Clin Pharmacol 2003; 58: 843-849.
60.Soucek, P., Gut, I., Trneny, M., Skovlund, E., Grenaker Alnæs, G., Kristensen, T., Børresen-Dale, A-L., and Kristensen, V.N. Multiplex single-tube screening for mutations in the Nijmegen Breakage Syndrome (NBS1) gene in Hodgkin’s and non-Hodgkin’s lymphoma patients of Slavic origin. Eur J Human Genetics 2003; 11: 416-419.
61.Smeland, S., Aas, M., Skovlund, E., Erikstein, B., Hess, S.L., and Fosså, S.D. Role of Strontium-89 as adjuvant to palliative external beam radiation is questionable: results of a double-blind randomised study. Int J Radiation Oncol Biol Phys 2003; 56: 1397-1404.
62.Bretthauer, M., Hoff, G., Thiis-Evensen, E., Huppertz-Hauss, G., and Skovlund, E. Air and carbon dioxide volumes insufflated during colonoscopy. Gastrointestinal Endoscopy 2003; 58: 203-206.
63.Breen, A.B., Vaskinn, T.E., Reikvam, Å., Skovlund, E., Lislevand, H., and Madsen, S. Warfarinbehandling og blødninger (Oral anticoagulants and bleeding). Tidsskr Nor Lægeforen 2003; 123: 1835-1837.
64.Madsen, S., Breen, A.B., Vaskinn, T.E., Reikvam, Å, Skovlund, E., and Lislevand, H. High INR-values responsible for adverse events (eletter). Rapid response to Odén and Fahlén, BMJ 2003; 325: 1073-1075.
65.Skovlund, E. Interim analyses in clinical trials. Heart Drug 2003; 3: 113-116.
66.Hoff, G., Bretthauer, M., Skovlund, E., and Grotmol, T. Re: Baseline findings of the Italian multicenter randomized controlled trial of “Once-only sigmoidoscopy” – SCORE (letter). JNCI 2003; 95: 1089-1090.
67.Reed, W., Hannisdal, E., Skovlund, E., Thoresen, S.Ø., Lilleng, P., and Nesland, J. Pregnancy and breast cancer: a population based study. Virchows Archiv 2003; 443: 44-50.
68.Hernes, E., Fosså, S.D., and Skovlund, E. Androgen-independent prostate cancer: The clinical problem of a growing pelvic tumour. Acta Oncol 2003; 42: 749-755.
69.Bretthauer, M., Skovlund, E., Grotmol, T., Thiis-Evensen, E., Gondal, G., Huppertz-Hauss, G., Efskind, P., Hofstad, B., Holmsen, S.T., Eide, T.J., and Hoff, G. Inter-endoscopist variation in polyp and neoplasia pick-up rates in flexible sigmoidoscopy screening for colorectal cancer. Scand J Gastroenterol 2003; 38: 1268-1274.
2004
70.Åsberg A and Holdaas H Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev Cardiovasc Ther 2004; 2(5): 641-652.
71.Hermann M, Åsberg A, Christensen H, Holdaas H, Hartmann A, Reubsaet JLE. Substantially elevated levels of atorvastatin and metabolites in cyclosporine A treated renal transplant recipients. Clin Pharm Ther 2004; 76(4): 388-391.
72.Molden E. P-glycoprotein - a pump of significance for drug response [in Norwegian]. Tidsskr Nor Lægeforen 2004;124:2921-3.
73.Molden E. Variability in cytochrome P450-mediated metabolism of cardiovascular drugs: Clinical implications and practical attempts to avoid potential problems. Heart Drug 2004;4:55-79.
74.Væth, M. and Skovlund, E. A simple approach to power calculations in regression models. Statist Med 2004; 23: 1781-1792.
75.Puska, P., Korpelainen, V., Høie, L., Skovlund, E., and Smerud, K.T. Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolemia: a double blind, placebo- controlled trial of a yoghurt formulation. Br J Nutr 2004; 91: 393-401.
76.Wyller, T.B., and Skovlund, E. Korrelerte parametre og annen språklig slendrian. (Språkspalten) Tidsskr Nor Lægeforen 2004; 124: 973.
77.Faye, R.S., Aamdal, S., Høifødt, H.K., Jacobsen, E., Holstad, L., Skovlund, E., and Fodstad, Ø. Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clinical Cancer Research 2004; 10: 4134-4139.
2005
78.Hjelmesæth J, Åsberg A, Müller F, Jenssen T, Hartmann A. New-onset posttransplantation diabetes mellitus: Insulin resistance or insulinopenia? Impact of immunosuppressive drugs, hepatitis C virus and cytomegalovirus infection. Current Diabetes Reviews 2005; 1(1): 1-10.
79.Carlsson KC, Hoem NO, Glauser T, Vinks AA. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. Clin Ther 2005; 27(5): 618-26.
80.Voytovich MH, Simonsen C, Jenssen T, Åsberg A, Midtvedt K, Hjelmesaeth J, Hartmann A. Short term treatment with rosiglitazone improves glucose disposal rate and endothelial function in renal transplant recipients with glucose intolerance. Nephrol Dial Transplant 2005; 20: 413-418.
81.Hermann M, Åsberg A, Christensen H, Reubsaet JLE, Holdaas H, Hartmann A. Atorvastatin does not affect pharmacokinetics of cyclosporine in renal transplant recipients. Eur J Clin Pharmacol 2005; 61: 59-62.
82.Hermann M, Christensen H, Reubsaet JL. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem. 2005; 382(5): 1242-9.
83.Molden E, Garcia BH, Braathen P, Egge AE. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol. 2005; 61(2): 119-25.
84.Molden E, Braathen P. Celecoxib is often combined with cytochrome P450 2D6 substrates in general clinical practice. Clin Pharmacol Ther. 2005; 78(1): 93.
85.Lemahieu WPD, Hermann M, Åsberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. Combined therapy with atorvastatin and calcineurin inhibitors: No interaction with tacrolimus. Am J Transplant 2005; 5: 2236-2243.
86.Hjelmesæth J, Åsberg A, Hartmann A, Jenssen T. New-onset diabetes mellitus after renal transplantation: diagnosis and treatment. Int Diabetes Monitor 2005; 5 (17): 15-21.
87.Thorsen, L., Skovlund, E., Strømme, S.B., Hornslien, K., Dahl, A.A., and Fosså, S.D. Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. J Clin Oncol 2005; 23: 2378-2388.
88.Skovlund, E., Bretthauer, M., Grotmol, T., Larsen, I.K., and Hoff, G. Sensitivity of pain rating scales in an endoscopy trial. Clin. J. Pain 2005; 21: 292-296.
89.Torlakovic, G., Torlakovic, E., Skovlund, E., Nesland, J.M., Reith, A., and Danielsen, H.E. Volume-related Sequence of Tumor Distribution Pattern in Prostate Carcinoma: Importance of Posterior Midline Crossover in Predicting Tumor Volume, Extracapsular Extension, and Seminal Vesicle Invasion. Croatian Medical Journal 2005; 46: 429-35.
90.Lund, K., Dunster, C., Ramis, I., Sandstrøm, T., Kelly, F.J., Søstrand, P., Schwarze, P.E., Skovlund, E., Boe, J., Kongerud, J., and Refsnes, M. Changes in inflammatory markers in bronchoalveolar lavage fluid from human volunteers 2 hours after hydrogen fluoride exposure. Hum Exp Toxicol 2005; 24: 1-8.
2006
91.Christensen H, Baker M, Tucker GT, Rostami-Hodjegan A. Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci. 2006; 95(12): 2778-87.
92.Åsberg A. Interacciones bilaterales entre ciclosporina A y tratamientos hipolipemiantes – The bilateral interactions between cyclosporine A and lipid-lowering therapies. Salud i Ciencia 20. February 2006;
93.Holdaas H, Hagen E, Åsberg A, Lund K, Hartmann A, Vaidyanathan S, Prasad P, He YL, Yeh CM, Bigler H, Rouilly M, Denouel J. Evaluation of pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharm Ther 2006; 44(4): 163-171.
94.Hermann M, Kase ET, Molden E, Christensen H. Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design. Curr Drug Metab. 2006; 7(3): 265-71.
95.Voytovich MH, Åsberg A, Hjelmesæth J, Jenssen T, Hartmann A. Association between insulin resistance and endothelial dysfunction in renal transplant recipients. Clin Transplant 2006; 20(2): 195-199.
96.Hermann M, Bogsrud M, Molden E, Åsberg A, Mohebi BU, Ose L, Retterstøl K. Exposure of atorvastatin is unchanged while lactone and acid metabolites are several-fold increased in patients with atorvastatin-induced myopathy. Clin Pharm Ther 2006; 79: 532-539.
97.Åsberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisæter AV, Johnsen LF, Fauchald P, Hartmann A. Calcineurin inhibitor-avoidance with daclizumab, mycophenolate mofetil and prednisolone in DR matched de novo kidney transplant recipients. Transplantation 2006; 82(1): 62-68.
98.Åsberg A, Hjelmesæth J, Voytovich MH, Hartmann A. Endothelial function in renal transplant recipients is associated with circulating nitric oxide, ACE inhibitor use and time after transplantation. Vasc Dis Prevent 2006; 3: 229-234.
99.Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable number of cigarettes on the interaction with olanzapine and clozapine. Eur J Clin Pharmacol 2006; 62: 1049-53.
100.Hendset M, Rudberg I, Haslemo T, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006; 39: 121-7.
101.Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006; 28: 744-49.
102.Rudberg I, Hendset M, Uthus LH, Molden E, Refsum H. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram. Ther Drug Monit 2006; 28: 102-5.
103.Drageset, V., Nesland, J.M., Erikstein, B., Skovlund, E., Sommer, H., Anker, G., Wist, E., Lundgren, S., Bergh, J., and Kvalheim, G. Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. Int. J. Cancer 2006; 118: 2877-2881.
2007
104.Åsberg A, Hansen CN, Reubsaet JLE. Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs. J Pharm Biomed Anal 2007; 43: 1039-1044.
105.Hjelmesæth J, Hagen LT, Åsberg A, Midtvedt K, Størset Ø, Halvorsen CE, Mørkrid L, Hartmann A, Jenssen T. The impact of short-term cyclosporine A treatment on insulin secretion and insulin sensitivity in man. Nephrol Dial Transpl, 2007; 22: 1743-1749.
106.Falck P, Guldseth H, Åsberg A, Midtvedt K, Reubsaet, JL. Determination of cyclosporine (CsA) and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS). J Chrom B 2007; 852: 345-352.
107.Åsberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz M, Sgarabotto D, Tuncer M, Noronha I, Hartmann A. A randomized multicenter study of the safety and efficacy of oral valganciclovir versus intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients: The VICTOR study. Am J Transpl 2007; 7: 2106-2113.
108.Molden E, Spigset O. Fruit and berries – interactions with drugs. Tidsskr Nor Laegeforen. 2007; 127(24): 3218-20.
109.Molden E, Andersson KS, Jacobsen D. Interactions between statins and macrolide antibiotics. Tidsskr Nor Laegeforen. 2007; 127(12): 1660-1.
110.Westergren T, Johansson P, Modlen E. Probable warfarin-simvastatin interaction. Ann Pharmacother. 2007; 41(7): 1292-5.
111.Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy. 2007; 27(4): 603-7.
112.Molden E, Westergren T. Interaction risk with statin switch. Tidsskr Nor Laegeforen. 2007; 127(4): 428-31.
113.Hendset M, Hermann M, Refsum H, Molden E. Impact of CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007; 63: 1147-51.
114.Thorsen, L., Dahl, A.A., Skovlund, E., Hornslien, K, and Fosså S.D. Effectiveness after 1 year of a short-term physical activity intervention on cardiorespiratory fitness in cancer patients. Letter. J Clin Oncol 2007; 25: 1301-1302.
115.Skovlund, E. Adaptive trial design and its role in oncology: An EMEA perspective. Eur J Cancer Supplements 2007; 5 (9): 43-44.
2008
116.Falck P, Vethe NT, Åsberg A, Midtvedt K, Bergan S, Reubsaet, JL, Holdaas H. Cinacalcet influence the pharmacokinetics of tacrolimus but not cyclosporine or mycophenolate in stable renal transplant recipients. Nephrol Dial Transplant 2008; 23: 1048-1053.